CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma

December 3-6, 2016; San Diego, California
Phase III study showed similar EFS and OS with both regimens and increased rate of adverse events with DA-EPOCH-R in DLBCL.
Format: Microsoft PowerPoint (.ppt)
File Size: 587 KB
Released: December 7, 2016


This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Related Content

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Updated data for epcoritamab + rituximab and lenalidomide in relapsed/refractory follicular lymphoma from EPCORE NHL-2, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings